Molsheim, France, November 9, 2021 – Merck, a leading science and technology company, today announced the retirement of Jean-Phillipe Maurer as Head of Molsheim Operations, effective December 1. Jean-Phillipe Maurer also served as President of the Millipore S.A.S. legal entity in France.
The Molsheim site is the third largest of the 52 global sites in Merck’s Life Science business sector. The site supplies a wide range of critical products to customers developing lifesaving therapies and has just added a new production unit for single-use assemblies, the first-of-its-kind for Merck in Europe.
For the past 40 years, Jean-Phillipe Maurer held multiple roles at Merck, leading the Molsheim team to considerable growth, navigating significant changes and advancements, and playing a key role in the building of Merck’s strong reputation in the Strasbourg region and across France.
Jean-Phillipe Maurer’s responsibilities will be shared between two leaders in France:
Jean-Phillipe Maurer
Romina Marcovici
Renaud Bardon
About Merck
Merck, a leading science and technology company, operates across healthcare, life science, and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
To continue reading please sign in or create an account.
Don't Have An Account?